Literature DB >> 11499690

Risk of breast and ovarian cancer in women with strong family histories.

A Srivastava1, W McKinnon, M E Wood.   

Abstract

Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities in several genes, including BRCA1, BRCA2, and TP53. Moderate-risk genes associated with syndromes that are inherited in an autosomal dominant pattern (such as Cowden's disease, hereditary non-polyposis colorectal cancer, Muir-Torre syndrome, and Peutz-Jeghers syndrome) exhibit lower penetrance and thus less risk of breast and/or ovarian cancer. Low-risk genes likely require significant environmental exposure, and although they are associated with the lowest risk of cancer, they account for more cancer than high- and moderate-risk genes. Lifetime risks for breast or ovarian cancer can be estimated. The Gail and Claus models, the more widely utilized models for calculation of lifetime breast cancer risk, are discussed. Models are also available for determining the likelihood of finding a BRCA1/2 mutation (the BRCAPRO and Myriad models). Appropriate candidates for testing include affected individuals who are most likely to have a hereditary form of cancer. Testing should proceed only after a thorough discussion of the risks, benefits, and limitations of testing. Risk-reducing options are available to women with a strong family history of breast and ovarian cancer. These options include high-risk screening, chemoprevention, and prophylactic surgery.

Entities:  

Mesh:

Year:  2001        PMID: 11499690

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  7 in total

Review 1.  Overview of personalized medicine in GI cancers.

Authors:  Celia Chao
Journal:  J Gastrointest Surg       Date:  2012-06-29       Impact factor: 3.452

2.  Acceptability of an mHealth breast cancer risk-reduction intervention promoting risk assessment, education, and discussion of risk in the primary care setting.

Authors:  Celia P Kaplan; Leah Karliner; Andrew Lee; Jennifer Livaudais-Toman; Jeffrey A Tice; Elissa Ozanne
Journal:  Mhealth       Date:  2021-10-20

3.  Assessing and managing breast cancer risk: clinical tools for advising patients.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2004-01-14

4.  KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients.

Authors:  Eunyoung Kang; Sue K Park; Jong Won Lee; Zisun Kim; Woo-Chul Noh; Yongsik Jung; Jung-Hyun Yang; Sung Hoo Jung; Sung-Won Kim
Journal:  J Hum Genet       Date:  2016-01-14       Impact factor: 3.172

5.  Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil.

Authors:  Edenir I Palmero; Maira Caleffi; Lavínia Schüler-Faccini; Fernanda L Roth; Luciane Kalakun; Cristina Brinkmann Oliveira Netto; Giovana Skonieski; Juliana Giacomazzi; Bernadete Weber; Roberto Giugliani; Suzi A Camey; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2009-09-01       Impact factor: 1.771

6.  Selecting a BRCA risk assessment model for use in a familial cancer clinic.

Authors:  Seema M Panchal; Marguerite Ennis; Sandra Canon; Louise J Bordeleau
Journal:  BMC Med Genet       Date:  2008-12-22       Impact factor: 2.103

7.  Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil.

Authors:  Edenir Inêz Palmero; Bárbara Alemar; Lavínia Schüler-Faccini; Pierre Hainaut; Carlos Alberto Moreira-Filho; Ingrid Petroni Ewald; Patricia Koehler Dos Santos; Patricia Lisbôa Izetti Ribeiro; Cristina Brinkmann de Netto Oliveira; Florence Le Calvez-Kelm; Sean Tavtigian; Silvia Liliana Cossio; Roberto Giugliani; Maira Caleffi; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2016-05-24       Impact factor: 1.771

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.